Barthélemy, Nicolas R. http://orcid.org/0000-0003-4937-2860
Saef, Benjamin
Li, Yan
Gordon, Brian A. http://orcid.org/0000-0003-2109-2955
He, Yingxin
Horie, Kanta http://orcid.org/0000-0001-7736-2614
Stomrud, Erik
Salvadó, Gemma
Janelidze, Shorena
Sato, Chihiro
Ovod, Vitaliy
Henson, Rachel L.
Fagan, Anne M.
Benzinger, Tammie L. S. http://orcid.org/0000-0002-8114-0552
Xiong, Chengjie
Morris, John C.
Hansson, Oskar http://orcid.org/0000-0001-8467-7286
Bateman, Randall J. http://orcid.org/0000-0002-7729-1702
Schindler, Suzanne E. http://orcid.org/0000-0002-1680-1465
Funding for this research was provided by:
Knight ADRC Developmental Award
Eisai industry award
U.S. Department of Health & Human Services | NIH | National Institute on Aging (P30AG066444, P01AG003991, P01AG026276, U19AG032438, U19AG024904, RF1AG061900, R56AG061900, R01AG070941)
Vetenskapsrådet (2016-00906)
Article History
Received: 17 October 2022
Accepted: 3 February 2023
First Online: 13 March 2023
Competing interests
: N.R.B., K.H., C.S., V.O. and R.J.B. are coinventors on the following US patent applications: ‘Methods to detect novel tau species in CSF and use thereof to track tau neuropathology in Alzheimer’s disease and other tauopathies’ (PCT/US2020/046224, N.R.B., K.H., C.S. and R.J.B.); ‘CSF phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies’ (PCT/US2022/022906, N.R.B., C.S. and R.J.B.); ‘Plasma based methods for detecting CNS amyloid deposition’ (PCT/UC2018/030518, V.O. and R.J.B.); and ‘Methods of diagnosing and treating based on site-specific tau phosphorylation’ (PCT/US2019/030725, N.R.B. and R.J.B.). N.R.B., K.H., C.S., V.O. and R.J.B. may receive a royalty income based on technology licensed by Washington University to C2N Diagnostics. K.H. is an Eisai-sponsored voluntary research associate professor at Washington University and has received a salary from Eisai. A.M.F. has received research funding from Biogen, Centene, Fujirebio and Roche Diagnostics. She is a member of the scientific advisory boards for Roche Diagnostics, Genentech and Diadem. She consults for DiamiR and Seimens Healthcare Diagnostics Inc. T.L.S.B. has investigator-initiated research funding from the NIH, the Alzheimer’s Association, the Barnes-Jewish Hospital Foundation and Siemens. She participates as a site investigator in clinical trials sponsored by Avid Radiopharmaceuticals, Eli Lilly, Biogen, Eisai, Janssen and Roche, and serves as a consultant to Biogen, Eli Lilly, Eisai and Siemens. C.X. consulted for DIADEM and has used funding from the NIH to hire C2N Diagnostics as a vendor in another independent NIH-funded project. He received no funding from C2N Diagnostics. Neither J.C.M. nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Fujirebio, Genentech, Novartis, Novo Nordisk, Roche and Siemens. R.J.B. cofounded C2N Diagnostics. Washington University and R.J.B. have equity ownership interest in C2N Diagnostics and receive a royalty income based on technology (stable isotope labeling kinetics, blood plasma assay and methods of diagnosing AD with phosphorylation changes) licensed by Washington University to C2N Diagnostics. R.J.B. receives an income from C2N Diagnostics for serving on the scientific advisory board, and has received research funding from Avid Radiopharmaceuticals, Janssen, Roche/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb and Novartis. S.E.S. has analyzed data provided by C2N Diagnostics to Washington University, but she has not received any research funding or personal compensation from C2N Diagnostics or any other for-profit organizations. The remaining authors declare no competing interests.